Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Startup Japanese Biotechs License Kyoto U.’s iPS Cell Process

This article was originally published in PharmAsia News

Executive Summary

A pair of Japanese startup biotech firms, Reprocell and Takara Bio, have signed licensing agreements with Kyoto University to use its patented production process for induced pluripotent stem cells. The agreements are the school's first for the iPS cells. Reprocell intends to screen for side effects of drug candidates by using the cells and test compounds on cultivated heart muscle cells. Takara Bio has begun selling a reagent used in cultivating iPS cells using a different method, but it plans to expand its reach with the Kyoto cells. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts